Review of 11 tirzepatide studies finds 21% mean weight loss at 72 weeks

The wire

1. 01A systematic review searched four databases to June 30, 2026 and included 26 publications from 11 parent studies, eight of them Phase III trials, finding dose-dependent weight loss approaching 21% at 72 weeks.
2. 02Findings support counselling patients that tirzepatide is maintenance therapy, since stopping led to progressive weight regain.
3. 03Heterogeneity prevented meta-analysis, so results were synthesised narratively; gastrointestinal adverse events were the most common and generally mild to moderate.

From the source

Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review

Cureus · 2026 Aug · Olaniyi AO, Gogineni KK, Olaniyi H et al.